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Cyclins D1, D2 and D3 play important roles in cell proliferation and differentiation. Although their abnormal expression has been
linked to cancer development and progression in a number of tissues, the expression of cyclin D2 and D3 proteins in colon cancer
has not yet been characterised. In this study, we examined cyclin D1, D2 and D3 protein expression by Western blot analysis in
tumour and adjacent normal colon tissues of 57 patients. In addition, we examined D-type cyclins protein expression in HT29 and
LoVo39 cell lines from colon carcinomas, as a function of induced proliferation and differentiation. In both cell lines, the expression of
the three D-type cyclins increased as a result of induced proliferation, whereas the expression of cyclin D3 increased as a result of
induced differentiation. In colon tumours, cyclin D1 was overexpressed in 44%, cyclin D2 was overexpressed in 53% and cyclin D3
was overexpressed in 35% of the cases. We also found that in 16% of the cases, cyclin D3 protein expression was reduced in the
tumour, as compared to the adjacent normal tissue. Examination of D-type cyclin protein overexpression in relation to the TNM
stage of the tumours revealed that overexpression of cyclins D1 and/or D2, but not cyclin D3, is linked to colon carcinogenesis and
that overexpression of cyclin D2 may be related to a higher TNM stage of the tumour.
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In proliferating eukaryotic cells, the progression from G1 phase to
S phase of the cell cycle is controlled by the expression of a subset
of cell cycle control genes. These include the D-type cyclins genes,
which consist of three family members, cyclin D1, D2 and D3. The
regulatory function of the D-type cyclins is mediated by their
interactions with cyclin-dependent kinases (CDK) 2, 4 and 6
(Matsushime et al, 1992) and the retinoblastoma susceptibility
gene product, Rb. Phosphorylation of Rb by cyclin D in complexes
with CDK4 or CDK6 in mid- to late G1 phase is believed to trigger
the onset of S phase by inducing the release of E2F transcription
factors from growth-inhibitory Rb complexes (Weinberg, 1995).
The free E2F proteins are believed to transcriptionally activate
genes involved in the activation and maintenance of DNA
synthesis.
Given the critical role of D-type cyclins in cell cycle regulation,
their abnormal or untimely expression has the potential to disrupt
the cell cycle, and therefore assign them as proliferation-
promoting genes or oncogenes (for reviews, see Bartkova et al,
1997; Lee and Yang, 2003). Indeed, overexpression of the D-type
cyclins has been reported in a large number of tumours (Sicinski
et al, 1996; Zhang, 1999; Zhang and Li, 1999; Florenes et al, 2000;
Ebert et al, 2001; Ito et al, 2001; Wong et al, 2001). However, not all
three D-type cyclins are overexpressed in the same tumour and the
three cyclins are differentially linked to poor outcome of the
disease. For example, overexpression of cyclin D2 in gastric cancer
was shown to correlate with disease progression and poor
prognosis (Yasogawa et al, 1998; Takano et al, 1999, 2000). On
the other hand, cyclin D2 mRNA and protein were absent in breast
cancer cell lines and primary cancer tissues, while in normal breast
epithelial cells, cyclin D2 was abundantly expressed (Evron et al,
2001). Overexpression of both cyclins D1 and D3 has been
observed in malignant melanomas (Florenes et al, 2000),
pancreatic cancer (Ito et al, 2001) and ductal carcinoma of the
breast (Wong et al, 2001). However, the linkage to prognosis was
different in all these cancers. In breast and pancreatic carcinomas,
cyclins D1 and D3 were differentially expressed, but neither was
linked to prognosis. On the other hand, in melanomas, cyclin D3,
but not D1, was clearly linked to poor clinical outcome (Florenes
et al, 2000). These reports clearly indicate a complex and perhaps
tissue-specific function of cyclins D1, D2 and D3 in cancer cells.
Therefore, to understand their contribution to carcinogenesis, a
detailed characterisation of their expression in cancers has to be
provided for each tissue.
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sOverexpression of cyclin D1 in colon cancer is well established
(Arber et al, 1996, 1999; Sutter et al, 1997; Bukholm and Nesland,
2000; Kristt et al, 2000; Holland et al, 2001; Utsunomiya et al,
2001). However, the linkage to prognosis is not clear (Bukholm
and Nesland, 2000). Cyclin D1 expression in colon tumours is
probably linked to its cell cycle-promoting activity in this tissue
since expression of cyclin D1 antisense inhibited growth and
tumorigenicity of human colon cancer cells (Arber et al, 1997). A
recent report indicated that in colon polyps, cyclins D1 and D2
seem to be overexpressed as compared to normal tissue, while the
expression of cyclin D3 in polyps is similar to that in normal colon
tissue (Bartkova et al, 2001), which suggests a differential function
of the three D-type cyclins in neoplastic transformation of the
colon.
Since the expression of cyclins D2 and D3 in colon cancer tissue
has not yet been demonstrated, in the present study we
characterise the expression of the three D-type cyclins in
malignant colorectal tissues and in cell lines from colon
carcinomas, as a function of induced proliferation and differentia-
tion. Our objective is to determine the role of the three D-type
cyclins in colon tumorigenesis and the relation of their expression
to the clinical outcome of the disease.
MATERIALS AND METHODS
Patients and tissues
Human colon tissues were obtained from the surgical specimens of
57 patients (37 male 20 female patients, mean age 66.5 years) who
had undergone surgical resections for primary sporadic colorectal
adenocarcinomas at the Soroka Medical Center. Tissue was
removed under a protocol approved by the Ethical Institutional
Review Board. Written informed consent was obtained from all
patients. A piece of the tumour and a piece of morphologically
normal colonic tissue were removed from a site that was 5cm from
the lesion and transferred to the laboratory. Samples were stored
frozen at  801C until use. A total of 10 tumours were located in the
right, three in transverse, 27 in the left colon and 17 in the rectum.
The tumours were classified into four stages according to the TNM
cancer staging system: stage I (T1–T2,N 0,M 0)( n¼9); stage II
(T3–T4,N 0,M 0)( n¼29); stage III (any T, N1–2,M 0)( n¼10); and
stage IV (any T, any N, M1)( n¼9). In addition, the tumours were
classified according to their grade: G1, moderately to well
differentiated (n¼14); G2, moderately differentiated (n¼38);
G3, poorly to moderately differentiated (n¼2); and G4, poorly
differentiated (n¼3).
Cell lines
We examined D-type cyclin protein expression in HT29 and
LoVo39 colon carcinoma cell lines. These two cell lines were
chosen because of their differential expression of cyclin D2, cyclin
D2 being expressed in LoVo39 cells, but not in HT29 cells (Lukas
et al, 1995). HT29 cells were grown in DMEM medium and LoVo39
cells were grown in DMEM/F-12 (HAM)1:1 (Beit Haemeq, Israel),
in equal volumes, at 371C in a humidified atmosphere of a 5% CO2
incubator (Tuttnauer, USA). Both media were supplemented with
10% fetal calf serum, 2mML -glutamine and 15 antibiotic–
antimycotic solution containing 10Uml
 1 penicillin, 10mgml
 1
streptomycin and 1250Uml
 1 nystatin (Beit Haemeq, Israel).
Induction of proliferation and differentiation
Cells were seeded at a density of 5 10
4cellsml
 1 and grown for
24h prior to treatment. Cell viability was assessed by Trypan blue
(Sigma, USA) dye exclusion assay. For induction of proliferation,
cells were first arrested in G1 phase of the cell cycle by incubation
in low-serum medium   0.5% serum for 24h for HT29 cells and
0.5% serum for 72h for LoVo39 cells. Then, cells were released
from arrest by replacing the low-serum medium by medium
containing 10% serum. For induction of differentiation, cells from
both cell lines were incubated in medium containing various
concentrations of sodium butyrate (NaB; Sigma, USA) for 24h.
Western blotting
Primary colon tissues (B20ml) were sonicated, homogenised in
MB1 buffer (0.5 M Tris/HCl pH 7.5, 0.5 M PIPES pH 6.8, 2mM
EDTA, 1mM EGTA, glycerol, 0.176mM NaCl and 0.02% Na azide)
and centrifuged for 20min at 41C. The supernatant was mixed with
sample buffer and boiled for 5min. Cell line lysates were prepared
by resuspending cells in 150ml of lysis buffer (50mM HEPES pH
7.5, 150mM NaCl, 10% glycerol, 1% Triton X-100, 1.5mM MgCl2,
1m M EGTA, 20mM sodium pyrophosphate, 50mM NaF, 3mM
EDTA and 2mM sodium orthovanadate) supplemented with
protease inhibitors complete cocktail (Boehringer Mannheim,
Germany) and 0.2mM DTT for 10min on ice. Lysates were
centrifuged and the supernatant was collected. Proteins (5–30mg)
were fractionated on 12% SDS–polyacrylamide gel and transferred
onto polyvinylidene fluoride membrane (Millipore, USA). Mem-
branes were blocked with 5% low-fat milk in phosphate-buffered
saline (PBS) and then incubated with the appropriate antibodies.
The membranes were then washed five times with PBST
(PBSþTween) plus 1% BSA, and incubated with horseradish
peroxidase-conjugated secondary antibody for 2h at room
temperature. After washing three times with PBST (PBSþTween)
plus 1% BSA, the protein bands were detected by Western lighting
plus chemiluminescence reagent (NEN, USA). A semiquantitative
approach was used to determine the degree of change in
expression of cyclin D-type proteins. For this purpose, Western
blot films were scanned and digitised. The intensity of a
rectangular area that included a band of interest was determined
by ImageJ software. We then carried out several normalisations
steps. The background of each band was subtracted by measuring
the intensity of the same rectangular area near the band of interest.
To normalise the total protein quantity in each sample, the band
intensity of cyclin D-type proteins was divided by the band
intensity of b-actin in the same sample. In proliferation-induction
experiments, cyclin D protein expression following release from G1
arrest was normalised to the expression at the t¼0 time point. In
the differentiation-induction experiments, cyclin D protein ex-
pression in NaB-treated samples was normalised to the control.
For each case of colon cancer patient, cyclin D protein expression
in the tumour was normalised to the expression in normal tissue.
To differentiate between cases that overexpress a cyclin D protein
from those that do not, we defined a value of 1.5-fold increased
expression in the tumour, relative to normal tissue, above which a
cyclin D protein was designated to be overexpressed. In order to
account for the heterogeneity of the tissues, 15 out of 57 cases (nos.
15–29) were examined in duplicate, yielding identical results (data
not shown).
Antibodies used in this study include anti-cyclin D1 (DCS-6),
anti-cyclin D3 (DCS-22) (NeoMarkers, USA); anti-cyclin D2 (C-17)
(Santa Cruz, USA); and actin (cp01) monoclonal mouse IgM
(Oncogene, USA).
mRNA analysis
Levels of carcinoembryonic antigen (CEA), mucin glycoprotein 3
(MUC3), cyclin D3 and b-actin were determined by reverse
transcription–PCR (RT–PCR) of total RNA extracted from HT29
and LoVo39 cells treated with NaB. Total RNA extraction was
performed with the RNeasy mini kit (Qiagen, Germany), with
DNase (Qiagen, Germany) treatment to ensure removal of genomic
DNA. The cDNA template was prepared using half of the RNA
samples, using the first-strand synthesis kit (ABgene, UK). Primers
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50-CAT GAT TGG AGT GCT GGT TG-30, antisense 50-ACC AAG
CCC AGC TCA TTT T-30, product size 270bp; MUC3, sense 50-
AGT CCA CGT TGA CCA CCA CTG C-30, antisense 50-TGT TCA
CAT CCT GGC TGG CG-30, product size 406bp; cyclin D3: sense
50-CCC GAA AGG CGC AGT TGC AGC-30, antisense 50-GCC AGT
GAT CCC TGC CAG CAG C-30, product size 422bp; and b-actin:
sense 50-ATG GAT GAT GAT ATC GCC GCG-30, antisense 50-CTA
GAA GCA TTT GCG GTG GAC GAT GGA GGG GCC-30, product
size 238bp. To visualise the amplification products, we performed
PCR (Biometra, Germany). Cycling conditions were as follows:
951C for 30s, annealing for 30s and 721C for 60s. The number of
cycles was 35. Annealing temperatures for each product were as
follows: 55.01C for cyclin D3 primers, 56.31C for CEA primers,
59.01C for MUC3 primers and 601C for b-actin primers. PCR
products (10ml) were fractionated on 2% agarose gel; DNA was
visualised by ethidium bromide staining and quantified by video
densitometry (ImageMaster, Amersham, Germany).
Cell cycle analysis
For cell cycle analysis, floating and adherent cells were fixed with
70% ethanol and stored at  201C for at least 24h. The fixed cells
were collected by centrifugation and resuspended in 0.1% Triton
X-100 and 30mgml
 1 RNase A type I-A (Sigma), at room
temperature, for 40min. Nuclear DNA was stained with 15mg
propidium iodide in PBS solution and DNA content was measured
by flow cytometry (FACSCalibur, Becton Dickenson, Mountain
View, CA, USA). Cell proportions in sub-G0/G1, S and G2/M
phases of the cell cycle were analysed using appropriate software.
For each sample, 10000 cells were scored.
Alkaline phosphatase assay
Alkaline phosphatase (ALP) activity assay was performed follow-
ing the biochemical technique described by Sabokbar et al (1994).
The assay was performed by adding 50ml of the p-nitrophenyl
phosphate substrate (Sigma, USA), final concentration 10mM,
dissolved in AMP-substrate buffer and 50ml of each test sample
(cell lysate) to a 96-well microtitre plate. The cell lysate was
prepared as follows: cells were washed with sterile PBS and
resuspended in the same solution. Then, the number of viable cells
was adjusted to 2 10
4 and 5 10
4 for HT29 cells and LoVo39
cells, respectively. The cell suspension was lysed by adding 1%
(vv
 1) Triton X-100 in PBS. The absorbance of the product
(p-nitrophenyl phosphate) at 405nm was measured at 371C, using
a Titertek Multiskan spectrophotometric plate reader (Molecular
Devices, CA, USA). Alkaline phosphatase activity was measured at
1min intervals, for 30min. Alkaline phosphatase activity in NaB-
treated cells was normalised to that in the control.
Statistical analysis
The difference between the groups overexpressing the different
D-type cyclins was evaluated by the two-tailed Fisher’s exact test.
RESULTS
Expression of D-type cyclins during induction of
proliferation
Since D-type cyclins are believed to be cell cycle-promoting agents,
we first studied their expression as a result of proliferation
induction in HT29 and LoVo39 cell lines from colon carcinomas.
In both cell lines, following release from serum starvation, an
increase of cell population in S phase (Figure 1A) and a decrease in
cell population in G1 phase (data not shown) were observed,
indicating that the cells entered a cell division cycle. Population of
cells in G2/M phase remained unchanged in both cell lines (data
not shown). Induction of proliferation induced an increase in the
expression of cyclin D1 in both cell lines (Figure 1B and C). The
maximal increase in cyclin D1 expression, about four-fold relative
to G1-arrested cells, was observed 8h following release for HT29
cells and 12h following release for LoVo39 cells, just at the
beginning of the S phase of the cell cycle (Figure 1). The two cell
lines exhibited differential expression pattern of cyclin D3 protein
as a function of proliferation induction. In HT29 cells, the increase
in cyclin D3 protein expression was moderate, only about 1.5-fold
as compared to G1-arrested cells (Figure 1B and C, left panel). On
the other hand, there was a four-fold increase in cyclin D3 protein
expression following proliferation induction in LoVo39 cells
(Figure 3B and C, right panel). Cyclin D2 protein expression
in LoVo39 cells was also elevated as a function of induced
proliferation. However, this increase was rather moderate (1.5-
fold) and was considerably smaller as compared to the increase in
expression of cyclin D1 and D3 proteins in the LoVo39 cell line
(Figure 3B, right panel). These results indicate that although the
three D-type cyclins participate in cell proliferation, their relative
contribution differs.
Expression of D-type cyclins during induction of
differentiation
It has been previously shown that induction of differentiation is
associated with elevation of cyclin D3 protein expression (Bartkova
et al, 1998, 1999; Siavoshian et al, 2000). Therefore, in the present
study, we examined the expression of D-type cyclins as a function
of induced differentiation in HT29 and LoVo39 cell lines (Figure 2).
Differentiation was induced by NaB, which is a well-known
differentiation inducer of colonic epithelial cells (Kim et al, 1980).
It has been demonstrated that NaB induces differentiation of
colon-derived cell lines into mucus-secreting goblet cells that
produce mucin glycoproteins and into absorptive enterocytes,
which are characterised by elevated ALP activity (Wice et al, 1985;
Schroy et al, 1994; Velcich et al, 1995; Gouyer et al, 2001).
Induction of differentiation was followed by measurement of ALP
activity in cell lysates (Colony and Neutra, 1983) and by RT–PCR
detection of mRNA levels of two differentiation markers, CEA
(Huitric et al, 1976; Velcich et al, 1995) and mucin 3 (MUC3)
(Velcich et al, 1995; Gouyer et al, 2001; Gaudier et al, 2004). In
both cell lines, 24h treatment with NaB resulted in elevation of
ALP activity (Figure 2A). In LoVo39 cells, ALP activity was
induced by relatively low, 0.1mM NaB concentration (Figure 2A,
right panel). In these cells, the maximal increase (B3.5-fold) in
ALP activity was observed at 1mM NaB. On the other hand, the
increase in ALP activity of HT29 cells occurred at higher NaB
concentrations and was more moderate, B2.5-fold at 5mM NaB
(Figure 2A, left panel). In addition, 1mM NaB increased mRNA
expression of CEA and MUC3 (Figure 2C), although in LoVo39
cells the increase in CEA mRNA was smaller compared to HT29
cells. We also observed that 5 days of treatment with 1mM NaB
induced the formation of what appears to be mucus-secreting
vesicles in both cell lines (data not shown). These results indicate
that NaB induces differentiation of HT29 and LoVo39 cell lines
into both mucus-secreting cells and enterocytes.
Induction of differentiation by NaB was followed by a significant
increase of cyclin D3 protein expression in both cell lines treated
with 1 and 5mM of NaB (Figure 2B). On the other hand, following
NaB treatment, the expression of cyclin D1 remained unchanged
while the expression of cyclin D2 decreased (Figure 2B). It has
been suggested that during differentiation, elevation of cyclin D3
protein levels is a result of protein stabilisation (Cenciarelli et al,
1999; Siavoshian et al, 2000). Therefore, we examined cyclin D3
mRNA levels by RT–PCR in HT29 and LoVo39 cells treated with
NaB (Figure 2C). In LoVo39 cells, the degree of elevation in cyclin
D3 protein levels (Figure 2B, right panel) and in cyclin D3 mRNA
Expression of D-type cyclins in colon cancer
A Mermelshtein et al
340
British Journal of Cancer (2005) 93(3), 338–345 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
slevels (Figure 2C, right panels) was similar at both concentrations
of NaB. In contrast, HT29 cells exhibited a different trend of
elevation of cyclin D3 protein levels compared to mRNA levels. In
these cells, which were treated with both 1 and 5mM NaB, cyclin
D3 protein expression was significantly higher than in untreated
cells (Figure 2B, left panel), while only a moderate elevation
(B20%) in mRNA levels was observed in cells treated with 1mM
NaB. No change was observed following 5mM NaB treatment
(Figure 2C, left panel). These results suggest that in both cell lines,
elevation in cyclin D3 protein levels following NaB treatment is at
least in part transcriptionally regulated. In addition, these results
clearly indicate that in HT29 cells, the differentiation-induced
increase in cyclin D3 protein levels is also post-transcriptionally
regulated.
Expression of D-type cyclins in normal and cancer colon
tissues
Typical examples of expression of the three D-type cyclins proteins
in tumour and adjacent normal colon tissue are shown in Figure 3.
In cases 30 and 32, there was marked elevation of cyclin D1 protein
levels, as compared to the adjacent normal tissue, while in case 31,
there was no difference between the expression of the cyclin D1
protein between normal and cancer tissue (Figure 3A). We found
that in agreement with previous reports (Arber et al, 1996, 1999;
Sutter et al, 1997; Bukholm and Nesland, 2000; Kristt et al, 2000;
Holland et al, 2001; Utsunomiya et al, 2001), cyclin D1 protein is
overexpressed in 25 of 57 examined cases (44%) (Table 1). Cyclin
D2 was also overexpressed in colon cancer tissue. For example, in
case 6, cyclin D2 protein was overexpressed in tumour, as
compared to the adjacent normal tissue. In cases 7 and 40, there
is no difference between the expression of the cyclin D2 protein in
normal and cancer tissue (Figure 3B). We found that in 30 of the 57
examined cases, cyclin D2 protein was overexpressed (53%)
(Table 1). Typical examples of cyclin D3 expression in colon
tissues are shown in Figure 3C. In cases 43 and 44, there was an
elevation of cyclin D3 protein level in the tumour tissue. On the
other hand, in case 48, there was similar expression of cyclin D3
protein in normal and cancer tissue. Unlike cyclins D1 and D2,
which are overexpressed in cancerous tissue, in some cases cyclin
D3 protein expression in the tumour was significantly lower (more
than 10-fold) as compared to normal tissue (case 47 in Figure 3C).
Cyclin D3 protein was overexpressed in 20 of 57 cases (35%) and
underexpressed in nine of the cases (16%).
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Figure 1 Expression of D-type cyclins during induction of proliferation. HT29 cells (left panels) and LoVo39 cells (right panels) were arrested in G1 phase
of the cell cycle by serum starvation and then released. As a function of time following release, cell cycle phase distribution was analysed by flow cytometry
(A), and D-type cyclin and b-actin protein expressions were analysed by Western blot analysis (B, C). In (B), representative Western blot analysis is
presented. The locations of bands of the D-type cyclins and b-actin proteins, based on their molecular weight, are indicated by arrows. Numbers on top of
each Western blot image represent the normalised expression of the various proteins (see Materials and Methods), relative to their expression at timeo f
release from G1 arrest (0h). Panel (C) displays the average relative expression of cyclin D1 (circles), D2 (squares) and D3 (triangles) as a function of time
following release. The points and bars represent average and s.d. of three independent experiments.
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sTables 1 and 2 summarise the results regarding D-type cyclin
protein expression. At least one D-type cyclin is overexpressed in
40 of 57 cases (70%), the majority (n¼39, 68%) overexpressing
either cyclin D1 or cyclin D2 (Table 1). This indicates that
overexpression of cyclins D1 and D2 is related to colon
carcinogenesis while overexpression of cyclin D3 is not. We also
found that in 15 cases (26%), a single cyclin D protein was
overexpressed in a given tumour, predominantly cyclin D2. In 15
cases (26%), two cyclin D proteins were overexpressed in the same
tumour, the majority being pairs including cyclin D2. In 10 cases
(17%), all three cyclin D proteins were overexpressed in the same
tumour (Table 1).
We were unable to link between cyclin D protein expression and
the grade of tumour differentiation, owing to the fact that the
distribution of the tumour grades was highly disproportional and
did not allow statistical analysis (see Materials and Methods).
Therefore, more studies are needed to determine whether the
overexpression of any of the D-type cyclins or underexpression of
cyclin D3 can be related to the differentiation grade of the
tumours.
We also examined the pattern of D-type cyclin overexpression in
relation to the TNM stage of the tumours. Among the 57 cases, 38
were classified as TNM stages I and II, whereas 19 were classified
as TNM stages III and IV in which metastases were found either in
the lymph nodes (stage III) or at remote organs such as the liver or
lungs (stage IV) (Table 2). There was no significant difference
between the expressions of the three cyclins in TNM stage I and II
tumours. On the other hand, the three D-type cyclins were
overexpressed to a different degree in higher (III and IV) tumour
stages. While the overexpression of cyclins D1 and D3 was similar,
cyclin D2 overexpression (68%) was higher than that of cyclin D1
(37%, P¼0.1) and cyclin D3 (32%, P¼0.05) proteins (Table 2).
The difference in overexpression between cyclin D1 and D2 did not
reach the significance limit of 95%, being only 90% (P¼0.1)
(Table 2). However, our results suggest a 90% significant
correlation between cyclin D2 protein overexpression and higher
tumour stages.
DISCUSSION
The main role of the three cyclin D family proteins is to promote
cell cycle progression from G1 to S phase (Lukas et al, 1994).
Indeed, we demonstrated that in two cell lines from colon
carcinomas, protein expression of all three D-type cyclins
increased as cells entered proliferation (Figure 1). Since most of
the colon-derived cell lines do not express the cyclin D2 protein,
this is the first study to indicate that in cell line from colon
carcinoma, cyclin D2 protein expression is also elevated as a
function of induced proliferation (Figure 1, right panels). In
LoVo39 cells, the expression of cyclin D2 protein increased to a
considerably smaller extent than cyclin D1 and D3 proteins
(Figure 1, right panels). In HT29 cells, however, the increase in the
expression of the cyclin D3 protein was significantly lower than
that of the cyclin D1 protein (Figure 1, left panel). These results
indicate that in different cell lines, D-type cyclins unequally
contribute to cell proliferation.
Cyclin D1 overexpression has been reported to occur in 40–70%
of colon tumours (Arber et al, 1996, 1999; Sutter et al, 1997;
Bukholm and Nesland, 2000; Kristt et al, 2000; Holland et al, 2001;
Utsunomiya et al, 2001). As such, 44% of cyclin D1 overexpression
in the present study (Table 1) is in agreement with previous
reports. Although overexpression and rearrangement of cyclin D1
gene are associated with tumour progression and/or poor
prognosis in various tumour types, in colon cancer the link to
prognosis is not clear (Bukholm and Nesland, 2000). We found
that cyclin D1 overexpression is distributed equally among various
TMN-stage tumours (Table 2), which indicates that in colon
cancer, the overexpression of cyclin D1 is not related to the
metastatic status of the tumour. This finding supports the idea that
in the colon tissue, there is probably no link between the
overexpression of cyclin D1 and prognosis.
In contrast to cyclin D1 protein, whose overexpression was
distributed equally between the different TNM tumour stages, our
data show a trend (P¼0.1, 90% significance) that may point
towards a positive relation between overexpression of cyclin D2
protein and higher TNM stage of the tumour (Table 2). This may
suggest that the overexpression of cyclin D2, and not that of
cyclins D1 and D3, is related to metastatic tumours. These results
are in agreement with reports that overexpression of cyclin D2, but
not of cyclin D1, in gastric cancer correlates with disease
progression and poor prognosis (Takano et al, 2000). In addition,
in flat and exophytic human colon adenomas, cyclin D2 was
overexpressed in considerably larger proportions than cyclin D1
(Bartkova et al, 2001). Taken together, these findings seem
to indicate that in the gastrointestinal tract, cyclin D2 acts as a
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Figure 2 D-type cyclins expression during induction of differentiation by
NaB. HT29 cells (left panels) and LoVo39 cells (right panels) were treated
with NaB for 24h. (A) Alkaline phosphatase (ALP) activity measured as a
function of increased NaB concentrations (indicated on the abscissa).
Columns and bars represent averages and s.d. of 3–4 experiments. (B)
Cyclins D3, D2 and D1 and b-actin protein expression as a function of 24h
treatment with 1 and 5mM NaB. Numbers at the top of the panels indicate
protein levels of the different D-type cyclins, relative to b-actin expression
and normalised to the relative expression in the control cells (0mM NaB).
Data are representative of 3–4 similar experiments. (C) mRNA expression
of CEA, MUC3, cyclin D3 and b-actin (indicated on the right) as a function
of 24h treatment with 1 and 5mM NaB. Numbers on top of the CEA,
MUC3 and cyclin D3 panels represent mRNA expression relative to
b-actin and normalised to relative expression of the corresponding gene in
control cells (0mM NaB). Data are representative of three experiments.
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transformation. Moreover, in colon polyps, the overexpression of
cyclin D2 was reported to be the most considerable aberration
among several G1-phase regulators (Bartkova et al, 2001),
indicating that the overproduction of cyclin D2 protein is an early
event in neoplastic transformation of the colon. As such, and being
positively correlated with the metastatic potential of the tumour
(this study), cyclin D2 expression may serve as an early marker for
colon tumorigenesis and for prediction of clinical prognosis of
colon cancer. It has been suggested that hypermethylation of the
CpG islands in the cyclin D2 promoter is related to the lack of
cyclin D2 protein expression in breast cancer (Evron et al, 2001),
prostate cancer (Padar et al, 2003) and gastric cancer (Yu et al,
2003), while hypomethylation of the CpG islands is related to the
elevated expression of cyclin D2 in gastric cancer (Oshimo et al,
2003). It is possible that the overexpression of cyclin D2 in colon
cancer is also related to promoter hypomethylation. Such cyclin D2
promoter hypomethylation may be an early event, which may
explain the observed cyclin D2 overexpression in colon polyps
(Bartkova et al, 2001) and possibly determine the metastatic
potential of the colon tumour (Table 2).
N
#30
T N
#31
T N
#32
HT29
D1
β-Actin
12 0 1 2 1 1.3
#6 #7 #40
HT29 LoVo39 N T N T N
β-Actin
D2
1 2.5 1 1.2 1 0.8
#47 #48 #43 #44
NN T T T T NN HT29
β-Actin
D3
1 0.05 1 0.8 1 14 1 17
T
A
B
C
T
Figure 3 Expression of D-type cyclins in colorectal tumours. Western blot analysis of cyclin D1 (A), cyclin D2 (B) and cyclin D3 (C) protein expression in
tumour (T) and adjacent normal (N) colon tissues. Representative results of several patients are shown (indicated by case number, on top). Protein extract
from HT29 cells was used as a positive control for cyclin D1 and D3 protein expression and as a negative control for cyclin D2 protein expression. Protein
extract from LoVo39 cells was used as a positive control for cyclin D2 expression. The locations of bands of the D-type cyclins and b-actin proteins, based
on their molecular weight, are indicated by arrows. Numbers on the bottom of each Western blot image represent the normalised expression of D-type
cyclin proteins in the tumour tissue (T), relative to their expression in the adjacent normal tissue (N).
Table 1 Cyclin D protein expression in colon tissue
Overexpression
Cyclin D protein n %
a
No cyclin D overexpression 17 30
At least one cyclin D protein in a tumour
D1, D2 or D3 40 70
D1 or D2 39 68
D1 25 44
D2 30 53
D3 20 35
Single D-type cyclin overexpression in one tumour
D1 5 9
D2 9 16
D3 1 2
Two D-type cyclins overexpression in the same tumour
D1 and D2 6 10
D1 and D3 4 7
D2 and D3 5 9
Three D-type cyclins overexpression in the same tumour
D1, D2 and D3 10 17
aCalculated out of the 57 examined cases.
Table 2 Cyclin D protein expression relative to tumour staging
Overexpression
TNM stage (n) Cyclin D proteins n %
a
I and II (38) D1 18 47
D2 17 45
D3 14 37
III and IV (19) D1 7 37
D2 13 68
D3 6 32
aCalculated out of the 38 cases for stages I and II and out of the 19 cases for stages III
and IV.
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redundant in promoting cell cycle progression, they have been
demonstrated to have other functions (Kato and Sherr, 1993). We
have shown that in both HT29 and LoVo39 cell lines, cyclin D3
protein expression increased as a function of induced differentia-
tion, while the expression of cyclins D1 and D2 remained
unchanged or decreased (Figure 2B). This is in agreement with
previous studies demonstrating a dual role for cyclin D3 protein
in both proliferation and differentiation in several cell types
(Bartkova et al, 1998, 1999; Siavoshian et al, 2000; Ito et al, 2001),
including colon-derived cell lines (Siavoshian et al, 2000). In
addition, it has been recently demonstrated that ectopic cyclin D3
expression induced differentiation-specific lamin reorganisation in
C2C12 myoblasts (Mariappan and Parnaik, 2005), which suggests
that ectopic cyclin D3 expression induces differentiation in these
cells. At this point, it is not known whether ectopic cyclin D3
protein expression can also induce differentiation in colon-derived
cells.
Although a growing amount of evidence has shown increased
levels of cyclin D3 protein during differentiation in a number of
cell lines and tissues, the mechanism by which increased cyclin D3
protein levels is related to differentiation is not clear. Data
regarding the kinase activity of the cyclin D3–CDK4 complex
during differentiation have revealed conflicting results. For
example, it has been shown that during the differentiation of
mouse 3T3-L1 adipocytes, protein levels of cyclin D3 and its
association with CDK4 increased, while the association of p27 CDK
inhibitor with this complex remained constant. Consequently,
cyclin D3–CDK4 kinase activity remained high during differentia-
tion in mature adipocytes (Phelps and Xiong, 1998). In addition, in
the embryonal carcinoma cell line NTERA-2, cyclin E-dependent
CDK2 activity, but not cyclin D3-dependent CDK4 activity, was
suppressed as a result of hexamethylene-bisacetamide-induced
differentiation (Baldassarre et al, 1999). On the other hand, during
myogenesis, cyclin D3 protein levels and its association with CDK2
and CDK4 increased but cyclin D3-dependent kinase activity was
markedly reduced (Kiess et al, 1995; Wang and Walsh, 1996).
These findings suggest that cyclin D3 may have differentiation-
related functions, which are CDK activity independent. It is clear
that additional work is required to elucidate the mechanism by
which increased cyclin D3 levels are related to differentiation of
colon cells.
Recent studies have identified unique cyclin D3-associating
proteins that are involved in protein transcription regulation but
are not bound to cyclins D1 and D2 such as the mammalian
transcription initiation factor 3 (Shen et al, 2004), 15-kDa cellular
retinoic acid binding protein II and the nuclear retinoic acid
receptor a (Despouy et al, 2003). It is possible that such proteins
are involved in other cyclin D3 functions that differ from the cell
cycle-promoting function. In addition, during skeletal muscle
differentiation, activity of cell cycle-promoting CDK2 kinase is
inhibited by interaction with the cyclin D3 and p27
kip1 proteins
(Chu and Lim, 2000), which could provide an alternative
mechanism of cyclin D3 differentiation function. Since among
the three D-type cyclins, only cyclin D3 protein is expressed in the
differentiated regions of normal colon crypt (Bartkova et al, 2001),
it is clear that elevated cyclin D3 protein levels observed in colon-
derived cell lines (Siavoshian et al, 2000, and this study) reflect a
unique role of this protein in differentiation of normal colon
tissue. The findings that cyclin D3 was uniquely overexpressed in
only one of the 57 cases (Table 1) and that in a subset of tumours
cyclin D3 protein expression was reduced as compared to normal
tissue (Figure 3C) support the notion that cyclin D3 plays an
important role in the differentiation of colon epithelial cells but
not in colon carcinogenesis.
To the best of our knowledge, this is the first report to
characterise the expression of the three D-type cyclins in colon
cancer tissue. Our data clearly indicate that overexpression of
cyclin D1 and D2, but not D3, is related to cancerous transforma-
tion of the colon. Furthermore, the data suggest that cyclin D2
protein overexpression may be related to a higher stage of the
tumour.
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